Targeting Autotaxin and Lysophosphatidic Acid in Pulmonary Fibrosis: Admilparant's Positive Results Show Continued Promise

Philip L Molyneaux^{1

2}, Paolo Spagnolo³

Affiliations

¹ National Heart and Lung Institute Imperial College London London, United Kingdom.
² Royal Brompton and Harefield Hospitals Guy's and St Thomas' NHS Foundation Trust London, United Kingdom.
³ Department of Cardiac, Thoracic, Vascular Sciences and Public Health University of Padua Padua, Italy.

Editorial

Philip L Molyneaux et al. Am J Respir Crit Care Med. 2025 Feb.

. 2025 Feb;211(2):148-150.

doi: 10.1164/rccm.202410-2018ED.

Philip L Molyneaux^{1

2}, Paolo Spagnolo³

¹ National Heart and Lung Institute Imperial College London London, United Kingdom.
² Royal Brompton and Harefield Hospitals Guy's and St Thomas' NHS Foundation Trust London, United Kingdom.
³ Department of Cardiac, Thoracic, Vascular Sciences and Public Health University of Padua Padua, Italy.

No abstract available

Comment on

Efficacy and Safety of Admilparant, an LPA₁ Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.
Corte TJ, Behr J, Cottin V, Glassberg MK, Kreuter M, Martinez FJ, Ogura T, Suda T, Wijsenbeek M, Berkowitz E, Elpers B, Kim S, Watanabe H, Fischer A, Maher TM. Corte TJ, et al. Am J Respir Crit Care Med. 2025 Feb;211(2):230-238. doi: 10.1164/rccm.202405-0977OC. Am J Respir Crit Care Med. 2025. PMID: 39393084 Clinical Trial.

1. Maher TM. Interstitial lung disease: a review. JAMA . 2024;331:1655–1665. - PubMed
1. Maher TM, Ford P, Brown KK, Costabel U, Cottin V, Danoff SK, et al. ISABELA 1 and 2 Investigators Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials. JAMA . 2023;329:1567–1578. - PMC - PubMed
1. Richeldi L, Schiffman C, Behr J, Inoue Y, Corte TJ, Cottin V, et al. Zinpentraxin alfa for idiopathic pulmonary fibrosis: the randomized phase III STARSCAPE trial. Am J Respir Crit Care Med . 2024;209:1132–1140. - PMC - PubMed
1. Raghu G, Richeldi L, Fernández Pérez ER, De Salvo MC, Silva RS, Song JW, et al. ZEPHYRUS-1 Study Investigators Pamrevlumab for idiopathic pulmonary fibrosis: the ZEPHYRUS-1 randomized clinical trial. JAMA . 2024;332:380–389. - PMC - PubMed
1. Corte TJ, Behr J, Cottin V, Glassberg MK, Kreuter M, Martinez FJ, et al. Efficacy and safety of admilparant, an LPA1 antagonist, in pulmonary fibrosis: a phase 2 randomized clinical trial. Am J Respir Crit Care Med . 2025;211:230–238. - PubMed